




The relative strengths and weaknesses of GYRE Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GYRE Therapeutics INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 172% points. The greatest weakness of GYRE Therapeutics INC is the variable Research and Development, reducing the Economic Capital Ratio by 6.7% points.

The company's Economic Capital Ratio, given in the ranking table, is 418%, being 198% points above the market average of 220%.

Input Variable	Value in 1000 USD
Assets, Current	127,743
Cost of Goods Sold	0
Intangible Assets	115
Liabilities, Current	11,349
Liabilities, Non-Current	1,136
Other Assets	60,082
Other Compr. Net Income	165
Other Expenses	3,617
Other Liabilities	1,179
Other Net Income	1,039
Other Revenues	57,860
Property and Equipment	1,639
Research and Development	49,087
Selling, General and Administrative Expense	13,193

Output Variable	Value in 1000 USD
Assets	189,579
Liabilities	13,664
Expenses	65,897
Revenues	57,860
Stockholders Equity	175,915
Net Income	-6,998
Comprehensive Net Income	-6,916
BaseVar	164,102
ECR before Limited Liability	371%
Economic Capital Ratio	418%